2025年10月7日, BEA-17实验性癌症药物向人类试验推进。 Beactica Therapeutics met with Sweden’s regulator on Oct. 7, 2025, to advance its experimental cancer drug BEA-17 toward human trials.

临床治疗学于2025年10月7日与瑞典医疗监管机构举行了首次正式会议,讨论BEA-17临床前期发展,BEA-17是针对治疗癌症的LSD1和CoREST的新药物候选者。 Beactica Therapeutics held its first formal meeting with Sweden’s medical regulator on October 7, 2025, to discuss the preclinical development of BEA-17, a new drug candidate targeting LSD1 and CoREST for cancer treatment. 该机构支持Beactia的人类试验计划,并列举了结肠癌和血浆瘤动物模型的可喜结果,在这种模型中,药物增强了免疫力和标准疗法。 The agency supported Beactica’s plans to move toward human trials, citing promising results in animal models of colon cancer and glioblastoma, where the drug enhanced immune and standard therapies. BEA-17可口述使用,可以跨越血脑屏障,它持有美国林业发展局用于血浆瘤的孤儿药品标识。 BEA-17 is orally available and can cross the blood-brain barrier, and it holds U.S. FDA Orphan Drug Designation for glioblastoma. 该公司利用其EclipsorTM平台,旨在解决严重未得到满足的医疗需求,但BEA-17仍然在调查中,没有证明对人类的安全或功效。 The company, using its Eclipsor™ platform, aims to address serious unmet medical needs, but BEA-17 remains investigational with no proven safety or efficacy in humans.